YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Profusa, Inc. Berkeley, CA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA) (the "Company") announced that it has received a letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("N…
Profusa, Inc. BERKELEY, California, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the contin…
Digital health specialist Profusa has inked an option agreement to acquire G3 Vision Labs and its subsidiaries, giving the company a route to add an arsenal of diagnostics to its commercial portfolio. Under the terms of the deal, Profusa c…
(RTTNews) - Profusa, Inc. (PFSA), a digital health company, announced the signing of an option agreement that provides Profusa the right and option to acquire G3 Vision Labs, Inc. and its subsidiaries, Med Screen Laboratories Inc., Dominio…
BERKELEY, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of an Option Agreement (the “Agreement”) which provides Pr…
(RTTNews) - Profusa, Inc. (PFSA), a digital health company focusing on biosensing technologies, announced that it has signed a non-binding term sheet to acquire of a privately held commercial-stage diagnostics and toxicology testing compan…
(RTTNews) - Today's top biotech gainers include Zhengye Biotechnology, a veterinary vaccine manufacturer, which surged, easing Nasdaq delisting concerns; Advanced Biomed, which gained after withdrawing its planned U.S. securities offering…
(RTTNews) - Profusa, Inc. (PFSA), a commercial-stage digital health company, announced that it ?led an amendment to e?ect a one-for-twenty-five (1:25) reverse stock split of its common stock. Following the news, PFSA closed Thursday's (02-…
(RTTNews) - Profusa, Inc. (PFSA) will implement a 1-for-25 reverse stock split effective July 7, 2026. Shares will continue trading under the ticker PFSA with a CUSIP number. The move reduces outstanding shares from about 13.2 million to 5…
Profusa, Inc. BERKELEY, California, July 02, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the contin…
BERKELEY, California, July 02, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitorin…
(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday. Pre-market movers give traders an early read on momentum, sentiment, and potential volatility for the trading day. Price swings before the opening bell t…
(RTTNews) - Pre-market trading is offering an early glimpse into biotech stocks likely to attract investor attention this Wednesday. Significant price moves ahead of the opening bell are being driven by clinical trial updates, public and p…
Profusa, Inc. BERKELEY, CA, May 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an…
Quantum Cyber (QUCY) more than doubled on May 14 after announcing an exclusive IP License Agreement with BP United and naming Peter O’Rourke as a director. The post-announcement momentum drove QUCY above its key moving averages (MAs), with…
Profusa, Inc. BERKELEY, CA, May 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an…
(RTTNews) - Profusa, Inc. (PFSA), a commercial-stage digital health company, on Monday announced a Letter of Intent to acquire PanOmics, a multi-omics diagnostics platform from BioInsights LLC, for a total consideration of $30 million, for…
Company secures scalable multi-omics diagnostics platform and launches Mayo Clinic partnership adding to Lumee real-time biochemistry monitoring platform to advance pancreatic cancer applications BERKELEY, CA, April 06, 2026 (GLOBE NEWSWIR…
Profusa, Inc. BERKELEY, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the contin…
(RTTNews) - Profusa, Inc. (PFSA) has taken a significant step toward commercializing its biosensor technology with the launch of its Lumee tissue-oxygen healthcare and research offerings, a move that also initiates the company's first comm…
Research-use-only offerings are commercially available, enabling immediate product and service revenue generation Targets the global CRO market of $47.9 billion in 2025 and growing at 7% CAGR BERKELEY, Calif, Jan. 16, 2026 (GLOBE NEWSWIRE)…
Study conducted at US sites evaluates LumeeTMin peripheral artery disease (PAD) patients BERKELEY, Calif, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health compan…
Study evaluates Lumee™ Oxygen tissue monitoring platform with transcutaneous partial pressure of oxygen (tcpO₂) in peripheral artery disease patients BERKELEY, Calif, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Compa…
Recapitalization reduced net debt to $14 million as of October 31; achieved key milestones to deliver potential 2026 revenue target BERKELEY, Calif, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA…
EU commercialization expected in early 2026; U.S. entry and expanded indications to follow as digital-health pioneer advances tissue-integrated biosensor platform BERKELEY, Calif, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa”…
Achieved key operational milestones establishing manufacturing capabilities to supply more than 2x the products required to achieve 2026 revenue targets BERKELEY, Calif, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Co…
Initial target markets for commercialization include Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia Expands distributor channel coverage to ~35% of European Union population with ~300,000 annual endovascular p…
Initial target markets for commercialization include Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia Expands distributor channel coverage to ~35% of European Union population with ~300,000 annual endovascular p…
* Profusa (NASDAQ:PFSA [https://seekingalpha.com/symbol/PFSA]) announced on Tuesday its second $1 million investment in digital treasury assets to hedge against macroeconomic uncertainties, in line with the company’s treasury management st…
BERKELEY, Calif, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of…
Pr. Yann Gouëffic and affiliates (FRANCE-PAD) cover ~8% of all CLTI cases in France BERKELEY, Calif, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pio…
MarketNewsUpdatesNews Commentary NEW YORK, Sept. 11, 2025 /PRNewswire/ — The global Diagnostic Biomarker market is experiencing unprecedented growth and is projected to continue to see substantial growth in years to come. A recent report f…
Profusa, Inc. Company expects early 2026 rollout in EEA; physician portal combines Lumee™ oxygen monitoring with NVIDIA NeMo to deliver AI-driven clinical workflows BERKELEY, Calif, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profus…
Company expects early 2026 rollout in EEA; physician portal combines Lumee™ oxygen monitoring with NVIDIA NeMo to deliver AI-driven clinical workflows BERKELEY, Calif, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Com…
Internationally recognized vascular surgeon, Dr. Koen Deloose provides patient access to latest innovative treatments and personalized care BERKELEY, Calif, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nas…
Led by Prof. Dr. Marianne Brodmann, PI of clinical studies for the Lumee™ Oxygen CE Mark, collaboration includes practice adoption and platform integration in cases and clinical study programs BERKELEY, Calif, Aug. 27, 2025 (GLOBE NEWSWIRE…